

COMPARISON OF CLINICAL TRIAL PHASES

	PHASE I	PHASE II	PHASE III	PHASE IV
OBJECTIVES:	Determine the metabolic and pharmacological actions and the maximally tolerated dose	Evaluate effectiveness, determine the short-term side effects and identify common risks for a specific population and disease	Obtain additional information about the effectiveness on clinical outcomes and evaluate the overall risk-benefit ratio in a demographically diverse sample	Monitor ongoing safety in large populations and identify additional uses of the agent that might be approved by the FDA
FACTORS TO BE IDENTIFIED:	<ul style="list-style-type: none"> -Bioavailability -Bioequivalence -Dose proportionality -Metabolism -Pharmacodynamics -Pharmacokinetics 	<ul style="list-style-type: none"> -Bioavailability -Drug-disease interactions -Drug-drug interactions -Efficacy at various doses -Pharmacodynamics -Pharmacokinetics -Patient safety 	<ul style="list-style-type: none"> -Drug-disease interactions -Drug-drug interactions -Dosage intervals -Risk-benefit information -Efficacy and safety for subgroups 	<ul style="list-style-type: none"> -Epidemiological data -Efficacy and safety within large, diverse populations -Pharmacoeconomics
DATA FOCUS:	<ul style="list-style-type: none"> -Vital signs -Plasma and serum levels -Adverse events 	<ul style="list-style-type: none"> -Dose response and tolerance -Adverse events -Efficacy 	<ul style="list-style-type: none"> -Laboratory data -Efficacy -Adverse events 	<ul style="list-style-type: none"> -Efficacy -Pharmacoeconomics -Epidemiology -Adverse events
DESIGN FEATURES:	<ul style="list-style-type: none"> -Single, ascending dose tiers -Unblinded -Uncontrolled 	<ul style="list-style-type: none"> -Placebo controlled comparisons -Active controlled comparisons -Well-defined entry criteria 	<ul style="list-style-type: none"> -Randomized -Controlled -2-3 treatment arms -Broader eligibility criteria 	<ul style="list-style-type: none"> -Uncontrolled -Observational
DURATION:	Up to 1 month	Several months	Several years	Ongoing (following FDA approval)
POPULATION:	Healthy volunteers or individuals with the target disease (such as cancer or HIV)	Individuals with target disease	Individuals with target disease	Individuals with target disease, as well as new age groups, genders, etc.
SAMPLE SIZE:	20 to 80	200 to 300	Hundreds to thousands	Thousands
EXAMPLE:	Study of a single dose of Drug X in normal subjects	Double-blind study evaluating safety and efficacy of Drug X vs. placebo in patients with hypertension	Study of Drug X vs. standard treatment in hypertension study	Study of economic benefit of newly-approved Drug X vs. standard treatment for hypertension